Congrats James Januzzi Jr MD !

Exemplary scientific leader and collaborator!

Look forward to working with you more and further collaborations to advance cardiovascular science

Exciting day as we kickoff #ARTEMIS trial testing Ziltivekimab in the #acuteMI setting with great team around the world.

Dr Roxana Mehran

Agree - what a great choice who continues inspire us all everyday

Congrats Robert Harrington

We need to bend the curve!

Reversals in the Decline of Heart Failure Mortality in the US, 1999 to 2021 jamanetwork.com/journals/jamac…

Duke Clinical Research Institute JAMA Cardiology JAMA

And Dr. Monica M. Bertagnolli and U.S. FDA discussing an exciting future with a better clinical trial infrastructure- everywhere for everyone

Duke-Margolis

Now Mandy K. Cohen, MD, MPH discussing priorities w/ CMSGov leadership noting we need interoperability of data w/ #fhir standards

1- least burdensome for more interoperable data network

2- offers system flexibility to address problems

3- value back to health systems

Duke-Margolis

Now Mary E. Klotman, MD discussing North Carolina as a national laboratory to develop, test and evaluate solutions to improve health

Examples- new care models for children, #GenerativeAI in care

Duke-Margolis Duke University School of Medicine

Themes
1- improve access
2- improve outcomes
3- improve value
4- all bipartisan goals

Duke-Margolis

Listening to Senator Thom Tillis and Secretary Kody Kinsley share innovative ideas about the future for better health through policy at the Duke-Margolis annual meeting

#CircACC24 #SimPub EMPACT-MI analysis: After acute myocardial infarction with left ventricular dysfunction or congestion, empagliflozin reduces the risk of heart failure hospitalizations #AHAJournals Adrian “WE NEED RCTS!” Hernandez @javedbutler1 ahajournals.org/doi/10.1161/CI…

#ACC24 #JACC LBCT SimPub: In #EMPACT -MI, #cvMI complicated by LV dysfxn or congestion portended a worse prognosis. Regardless of LV dysfxn severity or presence/absence of congestion, empagliflozin ⬇️ both first & total HF hospitalizations but not mortality in EMPACT-MI trial…

EMPACT-MI trial: Among patients hospitalized for acute myocardial infarction and at risk for heart failure, empagliflozin did not lead to a significantly lower risk of a first heart-failure hospitalization or death from any cause than placebo. nej.md/4cEb6EB

#ACC24

Great job Javed Butler on the EMPACT-mi trial presentation representing a global community

This trial was such an incredible journey starting at beginning of the pandemic and getting done through regional wars.

What a team effort! Schuyler Jones

Duke Clinical Research Institute Canadian VIGOUR Centre

Wow! Wake Forest University School of Medicine is getting a great leader, champion for improving health, impactful science and improving our communities outside the typical walls

Congrats Madhav Swaminathan !

What a privilege to welcome Tor Biering-Sørensen, MD, MSc, MPH, PhD to Duke Clinical Research Institute and have round table discussion with fellows to talk pragmatic trial design and more!

Nina Satoshi Shoji, MD, PhD Joe Lerman, MD Marat Fudim, MD MHS Robert Mentz, MD Adrian “WE NEED RCTS!” Hernandez Duke Cardiology Fellows

ICYMI: CardioHealthAlliance “Test to Treat” project, sponsored by Amgen 🧪🔬🧬 and led by Duke Clinical Research Institute Neha Pagidipati, aims to assess and gather data to improve quality of care for patients hospitalized for #ASCVD . More: bit.ly/4aeyfMg

Well-said!

A real champion for cardiology and the next generation

What a great group!